Free Trial

aTyr Pharma (ATYR) Competitors

aTyr Pharma logo
$5.83 +0.28 (+5.05%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$5.87 +0.04 (+0.67%)
As of 07/25/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATYR vs. KNSA, TWST, CNTA, BEAM, CGON, DNLI, HRMY, IRON, MESO, and BLTE

Should you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Disc Medicine (IRON), Mesoblast (MESO), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

aTyr Pharma vs. Its Competitors

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Kiniksa Pharmaceuticals International has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 9 mentions for Kiniksa Pharmaceuticals International and 8 mentions for aTyr Pharma. Kiniksa Pharmaceuticals International's average media sentiment score of 0.64 beat aTyr Pharma's score of 0.62 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals International
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than aTyr Pharma. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals International$481.17M3.99-$43.19M-$0.25-105.32
aTyr PharmaN/AN/A-$64.02M-$0.81-7.20

aTyr Pharma has a net margin of 0.00% compared to Kiniksa Pharmaceuticals International's net margin of -3.52%. Kiniksa Pharmaceuticals International's return on equity of -3.83% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals International-3.52% -3.83% -2.98%
aTyr Pharma N/A -87.09%-64.77%

Kiniksa Pharmaceuticals International presently has a consensus target price of $39.67, indicating a potential upside of 50.65%. aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 246.48%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals International
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
aTyr Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATYR vs. The Competition

MetricaTyr PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$518.89M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E Ratio-7.2021.3228.3920.08
Price / SalesN/A280.80430.0899.95
Price / CashN/A42.7636.2258.56
Price / Book7.028.378.675.88
Net Income-$64.02M-$55.19M$3.25B$258.89M
7 Day Performance-2.67%5.86%4.30%3.70%
1 Month Performance9.79%17.29%10.57%11.71%
1 Year Performance162.61%4.39%35.68%17.98%

aTyr Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATYR
aTyr Pharma
2.1562 of 5 stars
$5.83
+5.0%
$20.20
+246.5%
+161.4%$518.89MN/A-7.2053News Coverage
Gap Up
KNSA
Kiniksa Pharmaceuticals International
3.4549 of 5 stars
$28.42
-2.1%
$39.67
+39.6%
+1.6%$2.12B$423.24M-113.68220News Coverage
TWST
Twist Bioscience
4.3618 of 5 stars
$34.77
-1.1%
$50.40
+45.0%
-37.4%$2.11B$312.97M-10.70990News Coverage
Positive News
CNTA
Centessa Pharmaceuticals
3.3124 of 5 stars
$16.06
+2.4%
$28.10
+75.0%
+49.8%$2.10B$6.85M-8.87200News Coverage
Insider Trade
BEAM
Beam Therapeutics
2.259 of 5 stars
$21.03
+1.3%
$48.75
+131.8%
-32.5%$2.09B$63.52M-4.56510Analyst Revision
CGON
CG Oncology
2.6049 of 5 stars
$26.90
+0.6%
$55.30
+105.6%
-20.9%$2.04B$1.14M-17.8161Positive News
DNLI
Denali Therapeutics
4.2613 of 5 stars
$13.83
-1.2%
$33.71
+143.8%
-43.3%$2.03B$330.53M-5.18430News Coverage
Positive News
Upcoming Earnings
HRMY
Harmony Biosciences
4.7915 of 5 stars
$35.25
+0.1%
$51.00
+44.7%
+12.7%$2.02B$714.73M13.45200Positive News
Analyst Revision
IRON
Disc Medicine
3.3774 of 5 stars
$59.38
+2.8%
$95.73
+61.2%
+38.0%$2.00BN/A-15.1530News Coverage
Insider Trade
Gap Up
MESO
Mesoblast
1.497 of 5 stars
$14.65
-6.2%
$18.00
+22.9%
+120.5%$2.00B$5.90M0.0080Upcoming Earnings
Gap Down
BLTE
Belite Bio
1.7702 of 5 stars
$61.30
+0.6%
$96.67
+57.7%
+28.7%$1.94BN/A-45.0710

Related Companies and Tools


This page (NASDAQ:ATYR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners